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Summary The effects of the diatomic radical, nitric oxide (NO), on melphalan-induced cytotoxicity in Chinese hamster V79 and human MCF-7
breast cancer cells were studied using clonogenic assays. NO delivered by the NO-releasing agent (C2H5)2N[N(O)NO]-Na+ (DEA/NO; 1 mM)
resulted in enhancement of melphalan-mediated toxicity in Chinese hamster V79 lung fibroblasts and human breast cancer (MCF-7) cells by
3.6- and 4.3-fold, respectively, at the IC50 level. Nitrite/nitrate and diethylamine, the ultimate end products of DEANNO decomposition, had little
effect on melphalan cytotoxicity, which suggests that NO was responsible for the sensitization. Whereas maximal sensitization of melphalan
cytotoxicity by DEA/NO was observed for simultaneous exposure of DEA/NO and melphalan, cells pretreated with DEA/NO were sensitized
to melphalan for several hours after NO exposure. Reversing the order of treatment also resulted in a time-dependent enhancement in
melphalan cytotoxicity. To explore possible mechanisms of NO enhancement of melphalan cytotoxicity, the effects of DEANO on three factors
that might influence melphalan toxicity were examined, namely NO-mediated cell cycle perturbations, intracellular glutathione (GSH) levels
and melphalan uptake. NO pretreatment resulted in a delayed entry into S phase and a G/M block for both V79 and MCF-7 cells; however,
cell cycle redistribution forV79 cells occurred afterthe cells returned to a level of cell survival, consistent with treatment with melphalan alone.
After 15 min exposure of V79 cells to DEA/NO (1 mM), GSH levels were reduced to 40% of control values; however, GSH levels recovered
fully after 1 h and were elevated 2 h after DEA/NO incubation. In contrast, DEANO (1 mM) incubation did not reduce GSH levels significantly
in MCF-7 cells (approximately 10%). Melphalan uptake was increased by 33% after DEANNO exposure in V79 cells. From these results
enhancement of melphalan cytotoxicity mediated by NO appears to be complex and may involve several pathways, including possibly
alteration of the repair of melphalan-induced lesions. Our observations may give insights for improving tumour kill with melphalan using either
exogenous or possibly endogenous sources of NO.
Melphalan is awidely used chemotherapeutic agent foravariety of
tumour types and is thought to exert its cytotoxic effect by alkylat-
ing and cross-linking DNA (Calabresi and Parks, 1985; Colvin and
Chabner, 1990). Although melphalan has shown efficacy alone or
in combination with other chemotherapeutic agents, there remains
a need to explore avenues to broaden its spectrum and effective-
ness. Intracellular glutathione (GSH) levels have been shown to
modulate melphalan cytotoxicity, and depletion ofGSH by buthio-
nine sulphoximine (BSO) has been shown to enhance melphalan
cytotoxicity significantly (Green et al, 1984; Ozols et al, 1987).
Based on these preclinical findings, phase I clinical trials have
been completed recently establishing a safe BSO dose to use in
conjunction with melphalan (O'Dwyer et al, 1996).
We have examined the effects of nitric oxide (NO) on the cyto-
toxicity ofvarious agents and found that NO can modulate the cyto-
toxicity of various chemicals and ionizing radiation (Mitchell et al,
1993; Wink et al, 1993; Laval and Wink, 1994; Liebmann et al,
1994). NOis anendogenously producedradical thatevokes avariety
ofphysiological responses andhas been postulated to function in the
tumoricidal activity ofthe immune system (Hibbs et al, 1987; Stuehr
and Nathan, 1989). Furthermore, the enzyme nitric oxide synthase
(NOS) has been shown to be expressed in various tumours
Received 8August 1996
Revised 9 January 1997
Accepted 17January 1997
Correspondence to: DA Wink
(Asanoetal, 1994; Fastetal, 1992; Fienstein etal, 1994; Lepoivreet
al, 1994; Robbins et al, 1994; Thomsen et al, 1994), an observation
that suggests a potential endogenous source ofthis agent in vivo.
Because of the recent availability of chemical agents that can
release NO (Maragos et al, 1991) and our recent findings that NO
can enhance the cytotoxicity of BCNU (Laval and Wink, 1994),
we have studied the effect ofNO on the cytotoxicity ofmelphalan
in Chinese hamster V79 lung fibroblasts and human breast cancer
(MCF-7) cells. We report here that specific NO donor agents can
significantly enhance the cytotoxicity of melphalan and may
provide an interesting pharmacological approach for improving
the clinical efficacy ofmelphalan.
MATERIALS AND METHODS
Chemicals
DEA/NO {(C2H5)2N[N(O)NO]-Na+) was suppliedby DrJ Saavedra
and was prepared as previously described (Maragos et al, 1991). S-
nitrosoglutathione (GSNO) was synthesized asdescribedpreviously
(Saville, 1958). DEAINO stock solutions were made up in
0.02 N sodium hydroxide and the concentration was determined
spectrophotometrically by using an extinction coefficient of
8000 M-l cm-' at its characteristic absorbance band (247 nm)
(Mitchell et al, 1993). Hepes (N-[2-hydroxyethyl]piperazine-N'-[2-
ethanesulphonic acid]) and melphalan were purchased from Sigma
(St. Louis, MO, USA). L-buthionine sulphoximine (BSO) was
purchased from Schweizerhall (South Plainfield, NJ, USA).
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Cell culture
Chinese hamster V79 lung fibroblasts were cultured in F12
medium supplemented with 10% fetal calf serum and antibiotics.
Human breast cancer cells (MCF-7) were obtained from Dr Ken
Cowan (Medicine Branch, NCI, NIH, Bethesda, MD, USA) and
were grown in RPMI medium (Gibco BRL Gathersburg, MD,
USA) supplemented with 10% fetal calfserum and antibiotics. Cell
survival was assessed by clonogenic assay; plating efficiencies for
V79 and MCF-7 cells were 0.74 ± 0.1 and 0.52 ± 0.06 respectively.
Stock cultures of exponentially growing cells were trypsinized,
rinsed and plated (7x105 cells per dish) into a number of 100-cm2
Petri dishes and incubated for 16 h at 37°C before use in experi-
mental protocols. Cells were exposed to varying concentrations of
melphalan (0-4 jig ml-1) for 1 h. Final concentrations ofDEA/NO
or GSNO (1 mM) were added to parallel cultures immediately
before addition of melphalan. In control studies, DEA/NO (1 mM)
was allowed to decompose (denoted 'released DEAINO' on
survival curves) in full medium ovemight at 37°C before cell expo-
sure and added to parallel cultures immediately before addition of
melphalan. GSNO (1 mM) was allowed to decompose (denoted
'released GSNO' on survival curves) in full medium by exposing
the solution for 2 h at 365 nm UV (550 kJ m-2) (UV Trans-
illuminator, UVP, San Gabriel, CA, USA) before cell exposure and
added to parallel cultures immediately before addition of
melphalan. GSNO decomposure was tested using the RSNO (thiol-
nitric oxide) assay described by Cook et al (1996). For studies
involving GSH depletion before DEA/NO and/or melphalan treat-
ment, cells were pretreated with 0.5 mM BSO 15 h before experi-
mental procedures as described above. For all treatment conditions,
10 mm Hepes was added to the medium such thatthe pH was main-
tained at 7.2. Following treatment, the cells were washed twice
with phosphate-buffered saline (PBS), trypsinized, counted and
plated formacroscopic colony formation. Foreach dose determina-
tion, cells were plated into triplicate dishes and each experiment
was repeated a minimum of two times. Plates were incubated 7 or
10 days (V79, MCF-7 respectively), after which colonies were
fixed with methanol-acetic acid (3:1), stained with crystal violet
and counted. Colonies containing >50 cells were scored. Error bars
represent sd of the mean and are shown when larger than the
symbol. Survival curves were corrected for plating efficiency and
cytotoxicity for DEA/NO orreleased DEAINO where appropriate.
For studies involved in pretreating cells with eitherDEAINO or
decomposed DEA/NO for 1 h at 37°C and subsequently treating
with melphalan, the pretreatment solution was removed and the
cells were then rinsed twice with warm complete F12 medium,
fresh medium added and then incubated at 37°C. As a function of
time after DEAINO or released DEA/NO treatment, cells were
treated with melphalan (final concentration of melphalan for V79
and MCF-7 cells was 1.5 and 2.0 jg ml-1 respectively) for 1 h at
37°C. Following melphalan exposure, cells were plated for
survival assessment as described above. Additional studies were
conducted in which the order oftreatment was reversed.
Flow cytometry studies
Cells were exposed to 1.0 mm DEA/NO (and released DEA/NO)
for 1 h in a fashion identical to cell survival experiments described
above. Following treatment, cells were rinsed twice, fresh medium
added and incubated at 37°C. At various time intervals after treat-
ment, cells from each treatment group were harvested and fixed in
70% ethanol and stored for DNA analysis. Fixed cells were incu-
bated with 0.4 mg ml-' pepsin (Sigma) in 0.1 N hydrochloric acid
for 30 min at 37°C. Cells were spun out of the pepsin and resus-
pended in 10 mmborate (pH 8.7) to increase thepH andcentrifuged
immediately. Finally, the samples were resuspended in PBS
containing 10 ig ml-' propidium iodide (PI) to labelDNA. Samples
were analysed using an EPICS V cell sorter (Coulter Electronics,
Hileah, FL, USA) using 488 nm for PI excitation and > 530 nm
fluorescence for PI emission. DNA histograms were collected and
stored using the CICERO software (Cytomation, Ft Collins, CO,
USA). Cell cycle analysis was done using the Multicycle AV
DNA/cell cycle analysis software (Phoenix Flow Systems, San
Diego, CA, USA). The experiment was repeated twice.
Glutathione (GSH) measurements
Cells were treated with DEA/NO (1.0 mM) for 60 min at 37°C,
rinsed twice, fresh medium added and incubated at 37'C. Control
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Figure 1 Survival of V79 (A) and MCF-7 (B) cells exposed to varying
concentrations of melphalan for 1 h in the absence or presence of 1.0 mm
DEA/NO or released DEANO
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Ecoscint A (National Diagnostics, Atlanta, GA, USA) and counted
in a liquid scintillation counter (Beckman LS6500, Beckman
Instruments, Fullerton, CA, USA). Uptake experiments were
conducted three times, and the pooled data were analysed by the
ANOVA method (two-way analysis ofvariance).
NO detection using porphyrin-nafion coated electrode
Electrochemical experiments were conducted with a Princeton
Applied Research model 273 potentiostat/galvanostat with PAR
270 software (EG&G Princeton Applied Research, Princeton,
Simultaneous melphalan andDEA/NO NJ, USA). Single carbon fibre electrodes (Medical Systems,
I , I . I . I ,. , . , , , Greenvale, NY, USA)having dimensions of35 jm in diameter and
0 100 200 300 400 500 ~~~between 100 and 200gminlength were coated with nickel tetra-N-
Time afterDEA/NO orRel-DEA/NO methylpyridiniumporphyrin chloride (Ni(TMPP); MidCentury
treatment (min) Chemicals, Posen, IL, USA) as previously described (Wink et al,
B 1995a,b). Detection of NO was performed using an amperometric
technique at a constant potential of +0.7 V vs saturated calomel
Melphalan treatmentalone electrode (SCE) over a given period oftime and standardized with
Released DEA/NO known aliquots of NO as previously described (Wink et al,
1995a,b). Based on NO-standardized curves, NO concentration
T~ ~ values reported are accurate to± 5%. Measurements ofNO derived
from the NO donor complexes were conducted in a thermostated
cell maintained at 37°C in F12 medium supplemented with 10%
DEANO fetal calfserum without phenol red. Phenol red interferes with elec-
trochemical detection ofNO. Full medium (withoutcells) was used
forthese studies to simulate conditions that cells wouldexperience
when NO donor agents were added. Experiments were performed
by first equilibrating the electrode until the baseline had stabilized;
Simultaneous melphalan and DEA/NO at which point the NO donor was introduced. Experiments were
I .-I
. I . . replicated three times. The nickelporphyrin carbon fibre electrode
0 100 200 300 400 500 is quite stable and has a sensitivity range of 100 nm NO as previ-
ously reported (Christodoulou et al, 1996; Wink et al, 1995a).
lime after DEA/NO or Rel-DEANO
treatment (min)
Figure 2 Time course of DEANO mediated enhancement of melphalan
cytotoxicity for V79 (A) and MCF-7 (B) cells. For these studies, DEANO
treatment preceded melphalan treatment
and DEA/NO treated cells were sampled during and after DEAINO
treatment. The samples (in triplicate) were prepared by rinsing the
cell monolayer twice with cold PBS and then treating with 0.6%
sulphosalicylic acid (4°C) for 5 min. Quadruplicate samples of
each condition were assessed for GSH by the monobromo-
bimane-HPLC method (Cook et al, 1991). The total GSH levels
for untreated V79 and MCF-7 cells were 1.1 and 31.9 fmol per cell
respectively (Cook et al, 1991). Data are expressed as per cent of
control values ± s.e.m. and experiments were replicated twice.
[14C]melphalan uptake studies
The effects of DEA/NO or released DEA/NO treatment on V79
cells with respect to melphalan uptake was studied using identical
conditions for cell survival procedures as described above. Cells
were exposed to radiolabelled melphalan (1.0 gCi ml-', melphalan,
[chloroethyl-1,2-t4C], 50 mCi mmol-', Moravek Biochemicals,
Brea, CA, USA) for 1 h in the absence or presence of DEA/NO or
released DEA/NO (1 mm, final concentration). Following treatment,
cells were rinsed, trypsinized, counted, and aliquots of 105 cells (in
triplicate) were placed in scintillation vials containing 10 ml of
RESULTS
Effect of NO on melphalan cytotoxicity
Treatment ofV79 cells with melphalan alone resulted in a concen-
tration-dependent increase in cell killing, as shown in Figure IA.
To determine the effects of NO on melphalan-mediated cytotoxi-
city, we used a member of the class of compounds known as
NONOates (DEA/NO), which spontaneously release NO over a
specific time period (Maragos et al, 1991). DEA/NO treatment
alone resulted in a 50% reduction in survival for V79 cells.
Treatment of cells with 1.0 mm DEAINO simultaneously with
varying concentrations of melphalan resulted in increased
melphalan cytotoxicity (Figure IA). The enhancement in
melphalan cytotoxicity by DEA/NO was approximately 3.6- and
2.2-fold at the IC50 and IC9 levels respectively. Using 0.1 mM
DEAINO, the enhancement factor for an IC9 was 1.4 (data shown
in Figure 4, see below). In contrast, released DEA/NO, which
showed no cytotoxicity to V79 cells alone, did not enhance
melphalan cytotoxicity; in fact, modest protection was observed.
The use ofreleased DEA/NO was considered an important control
because it evaluates if the decomposition products of DEA/NO
(namely diethylamine and nitrite) could possibly effect melphalan
cytotoxicity. As released DEA/NO did not enhance melphalan
cytotoxicity, it can be concluded that NO released from DEA/NO
enhanced the melphalan cytotoxicity. Similar findings were found
for human MCF-7 cells as shown in Figure lB. For MCF-7 cells,
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Figure 3 Flow cytometric DNA analysis of V79 cells treated with 1.0 mM DEA/NO and followed as a function of time after treatment
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Table 1 Cell cycle analysis for V79 cells treated with 1 mm DEANO for 1 h
Time after GI (%) S(%) G/M (%)
DEAINO (h)
0 39 51 10
1 40 51 9
2 39 50 11
3 38 57 5
4 39 52 9
5 17 69 14
6 5 80 15
7 2 58 40
Table 2 Cell cycle analysis for MCF-7 cells treated with 1 mm DEA/NO for
1 h
Time after G, (%) S (%) G/M (%)
DEAINO (h)
0 29 47 24
1 30 54 16
2 23 66 11
3 30 54 16
4 34 51 15
5 24 70 6
6 25 65 10
7 20 63 17
DEAINO treatment also enhanced melphalan cytotoxicity
(enhancement at the IC50 was approximately 4.3), whereas
released DEAINO had no effect on melphalan cytotoxicity.
DEA/NO and released DEA/NO treatment alone both resulted in a
60% reduction in survival for MCF-7 cells.
Studies were next designed to determine the time course of
enhanced melphalan cytotoxicity by DEAINO. For these studies,
cells were first treated with DEA/NO orreleased DEAINO for 1 h.
Following DEAINO pretreatment, cells were rinsed free of
compound and incubated at 37°C in fresh medium. As a function
of time after DEAINO treatment, cells were treated with a fixed
concentration of melphalan for 1 h. Figure 2 shows for both V79
and MCF-7 cells thatthe enhanced melphalan cytotoxicity seen for
simultaneous treatment with DEAINO and melphalan (Figure 1)
was also observed following DEA/NO treatment. For V79 cells
enhancement of melphalan-induced cell killing by DEAINO
persisted (although not to the extent observed for simultaneous
treatment) for at least 30 min, after which there was a steady
increase in survival that by 240 min approached that ofmelphalan
treatment alone (Figure 2A). Pretreatment with released DEA/NO
did not significantly enhance melphalan cytotoxicity throughout
the time course. Figure 2B illustrates qualitatively similar findings
for MCF-7 cells. For MCF-7 cells, enhancement of melphalan
cytotoxicity was observed throughout the time course studied.
Enhancement was greatest from 0 to 120 min afterDEA/NO treat-
ment and then there was a gradual increase in survival that came
near but never actually reached the melphalan-alone survival level
by 450 min. Released DEAJNO treatment did not exert effects on
melphalan cytotoxicity (Figure 2B). Collectively, the data in
Figures 1 and 2 show that, although melphalan cytotoxicity was
enhanced by simultaneous DEAINO treatment, enhancement
could also be observed for considerable time after DEA/NO treat-
ment. With time, the enhancement in melphalan cytotoxicity by
DEA/NO pretreatment diminishes, which was variable according
to cell type.
Melphalan cytotoxicity has been shown to exhibit cell cycle
dependency (Meyn and Murray, 1986). To determine if DEAINO
treatment imposed any perturbations in the cell cycle of V79 or
MCF-7 cells that might influence subsequent melphalan cytotoxi-
city, flow cytometry studies were conducted. Figure 3 shows the
DNA flow cytometry results for V79 cells treated with 1 mm
DEA/NO for 1 h then washed and followed fortimes up to 7 h. No
major changes in the cell cycle were observed until 5 h, when the
cell cycle distributions indicated a delayed entry into S-phase
(Figure 3F). This synchronous entry into and through S-phase
would indicate that the cells must have been delayed at a specific
point at the G1/S border. In addition, GI continued to decrease and
G2JM continued to increase after 5 h (Table 1), which indicates that
a G2/M block must also have occurred. Released DEA/NO had no
effect on the cell cycle of any time points examined (data not
shown). Thus, NO released by DEAINO has profound cell cycle
effects, but these effects do not begin to become evident until 5 h
after DEA/NO treatment. The MCF-7 cells treated with DEAINO
responded in a similar fashion. A decrease in G1 and a synchro-
nous increase in S was observed after 7 h; however, the effect was
much reduced compared with V79 cells (Figure 4 and Table 2).
Experiments were next conducted where the order ofDEA/NO
or released DEA/NO and melphalan treatments were reversed. As
shown in Figure 5, if melphalan treatment preceded DEAINO
treatment, time-dependent enhancement in melphalan cytotoxicity
was observed for both cell lines similar to that shown in Figure 2.
A different type of NO-releasing agent was next evaluated.
GSNO, a S-nitrosothiol NO donor agent, did not modify melphalan
cytotoxicity in V79 cells, as shown in Figure 6. GSNO treatment
aloneresulted in nocytotoxicity. Likewise, decomposed GSNO was
not cytotoxic alone and had no influence on melphalan cytotoxicity.
Effects of DEA-NO treatment on intracellular GSH
levels
As depletion of intracellular GSH levels has been shown to
enhance the cytotoxicity ofmelphalan (Green et al, 1984; Ozols et
al, 1987), we conducted experiments to determine if DEA/NO
treatment lowered GSH levels. Table 3 shows that a 15-min expo-
sure to DEA/NO reduced GSH levels in V79 cells by approxi-
mately 60%; however, after 60 min GSH levels had returned to
control levels, and by 120 min there was a substantial increase in
GSH levels (205% ofcontrol). In contrast, DEAINO treatment did
not significantly alter GSH levels in MCF-7 cells (approximately
10% at 15 min) (Table 3).
Effects of DEAINO treatment on melphalan uptake
The enhancement of melphalan cytotoxicity by DEAINO might
result from increased cellular uptake ofmelphalan. To explore this
possibility, V79 cells were treated with radiolabelled melphalan in
the absence or presence of 1 mm DEA/NO or released DEA/NO
for 1 h (culture conditions identical to cytotoxicity experiments
cited above). Melphalan uptake for control, DEAINO and released
DEA/NO treatments was 754 ± 98, 1000 ± 73, and 791 ± 91 d.p.m.
respectively. DEAINO treatment resulted in a significant increase
(approximately 33%) in melphalan uptake (P < 0.01), whereas
released DEA/NO treatment had no significant effect on
melphalan uptake.
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Figure 4 Flow cytometric DNA analysis of MCF-7 cells treated with 1.0 mm DEA/NO and followed as a function of time after treatment
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Table 3 Effect of DEA/NO treatment on GSH levels in V79 and MCF-7 cells
GSH levels (% of control)
Time (min) V79 MCF-7
15 39±5 90±1
60 103±7 95±4
120 210±8 96±2
Comparison of BSO and DEA/NO treated cells
Because GSH is known to modulate melphalan cytotoxicity
(Green et al, 1984; Ozols et al, 1987), we studied the interaction of
DEA/NO with another GSH-depleting agent, BSO. V79 cells were
incubated with 0.5 mm BSO for 15 h and then incubated with
various concentrations of melphalan (Figure 7). BSO treatment
alone was not cytotoxic. Treatment with 0.5 mm BSO reduced
GSH levels to < 5% of control values and substantially increased
melphalan cytotoxicity, which is consistent with previous reports
Melphalan (gg ml-')
Figure 7 Survival of V79 cells exposed to varying concentrations of
melphalan for 1 h in the absence of presence DEANO (0.1 mM) or BSO
(0.5 mm, 15 h pretreatment) treated cells
(Green et al, 1984; Ozols et al, 1987). The enhancement ratio at the
IC 9 was 3.7. Because BSO increases DEA/NO cytotoxicity, 0.1 mM
DEA/NO was used for the melphalan studies. This concentration of
DEA/NO, which releases lower amounts of NO (see Figure 8
below), increased the melphalan cytotoxicity with an enhancement
ratio at the IC9 of 1.4. Combining 0.1 mM DEA/NO with BSO
further increased the melphalan sensitization compared with BSO
alone (enhancement ratio at theICg, ofapproximately 4.9).
No chemistry of NO donor compounds
A NO-sensitive electrode was used to determine NO concentra-
tions as a function oftime, resulting from NO donor agents under
conditions similar to cell survival studies (Wink et al, 1995b).
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Figure 8 Electrochemical determination of NO concentrations during 1 h
exposure DEA/NO (1.0 and 0.1 mM) and 1.0 mm GSNO in cell culture media
using a NO-sensitive electrode. The measurements were done in a F12
medium supplemented with 10% fetal calf serum containing 25 mm Hepes,
pH 7.2, at 370C in an open water-jacketed electrochemical cell while stirring.
Stock solutions of the NO donorcomplex were introduced such that the final
concentration was 0.1 mm DEA/NO, 1.0 mm DEA/NO and 1.0 mm GSNO
Figure 8 shows that introduction of 1 mM DEA/NO to cell culture
medium results in a rapid increase in NO that reaches a peak of
40 gM within 300 s and then decays to about 1 gM over 1 h. When
the same experiment was repeated with 0.1 mmDEA/NO, a rise in
NO was again observed, but only to 11 gM, which decayed to less
than 0.5 gM after 0.5 h. When 1 mm GSNO was used as the NO
donor, an initial increase in NO was observed thatpeaked at 3.5gM
and thendecayed to 0.5 gM, a value that remained constant for 1 h.
DISCUSSION
Studies over thepast few years have identified NO as animportant
and versatile free radical molecule in cells and tissues. Along with
its bioregulatory roles and involvement in the immune defence
system, the present study clearly demonstrates that NO can
enhance the cytotoxicity of the commonly used antineoplastic
drug melphalan. NO significantly increased the cytotoxicity of
melphalan in both V79 and MCF-7 cells. The enhancement
depended both on the particular NO donor agent and on the
concentration of donor used. GSNO was ineffective compared
with DEA/NO in modifying melphalan cytotoxicity. The reason
for the observed differences between NO donor drugs is most
readily explained by noting the NO release profiles of the donors.
For equimolar concentrations, DEA/NO released significantly
more NO than did GSNO (Figure 8) and 0.1 mMDEA/NO had a
peak release of 11JIMcompared with 42 gMfor 1 mMDEN/NO.
Treating cells with melphalan and NO simultaneously resulted
in maximal sensitization; however, pretreatment of cells with NO
also sensitized cells to melphalan. Sensitization was evident long
after NO had been washed from the cells. V79 cells almost
completely returned to melphalan-alone cytotoxicity levels by
240 minafter DEA/NO treatment, whereas MCF-7 cells still had
not returned to control levels by 450 min. The fact that NO
pretreatment sensitized cells to melphalan suggests that the pres-
ence of NO (in sufficient concentrations) may interfere with
cellular functions, such as repair of melphalan damage, that
renders the cell more susceptible to subsequent melphalan treat-
ment. Melphalan cytotoxicity has been shown to vary as a function
of cell cycle position, with cells in S-phase being approximately
threefold more resistant than cells in G1 or G/M (Meyn and
Murray, 1986). If DEAINO pretreatment resulted in a cell cycle
redistribution in S-phase, a decrease in melphalan cytotoxicity
might be expected. The data shown in Figures 3 and 4 and Tables
1 and 2 indeed indicate that DEA/NO treatment does redistribute
cells into S phase; however, this redistribution occurs aftercells (at
least V79 cells) return to a level of cell survival consistent with
melphalan-alone treatment (see Figure 2A). MCF-7 cells showed a
qualitiatively similar cell cycle profile after DEA/NO treatment;
however, these cells had not returned to the melphalan treatment-
alone survival level by 450 min. The reason for the differences in
the two cell types is not clear. These data support the notion that
DEA/NO treatment inhibits the repair of melphalan damage. To
test this hypothesis further, we conducted experiments in which
the order of melphalan and DEA/NO treatments were reversed
(Figure 5). Here again, DEA/NO enhanced melphalan cytotoxicity
initially, followed by a gradual return to melphalan-alone cyto-
toxicity survival levels. These data argue against cell cycle effects
playing a majorrole in the observed NO-mediated enhancement of
melphalan cytotoxicity.
Two factors in the NO-mediated enhancement of melphalan
cytotoxicity were studied: GSH levels and melphalan uptake.
First, the effects of DEAINO on intracellular GSH levels were
evaluated. Modulating GSH levels has been demonstrated to influ-
ence melphalan cytotoxicity (Green et al, 1984; Hamilton et al,
1985; Russo et al, 1986; Kramer et al, 1987; Ozols et al, 1987;
Skapek et al, 1988; Canada et al, 1993). GSH depletion by BSO
enhances melphalan cytotoxicity. The presence of NO in an
aerobic environment has been shown to reduce GSH levels
(Walker et al, 1995). It has been demonstrated in chemical studies
that reactive nitrogen oxide species (RNOS), formed from the
NO/O2 reaction, react rapidly with GSH to form GSNO (Wink et
al, 1994; Walker et al, 1995). As 1 mm DEA/NO treatment
reduced GSH levels in V79 cells by 60% within 15 min, it might
be assumed that either the reduction in GSH or the intracellular
formation of GSNO may contribute to the increased melphalan
cytotoxicity. Several points, however, contradict that conclusion;
(1) GSH levels recovered to control levels by 1 h and by 2 h actu-
ally superseded control GSH levels (Table 3), and (2) GSNO
added extracellularly did not enhance melphalan cytotoxicity.
With respect to the first point, melphalan cytotoxicity was still
increased by 2 h even though the GSH levels were 205% of
control. Furthermore, cells that were previously depleted of GSH
by BSO were still sensitized to melphalan by DEA/NO (Figure 7).
Although the sensitization was not completely additive, the result
suggests that NO sensitizes cells to melphalan by a pathway that
may be independentofGSH. Finally, MCF-7 cells were also sensi-
tized to melphalan even though very little GSH was depleted by
DEA/NO (Table 3).
We next determined if DEAINO treatment could affect the
cellular uptake of melphalan. Exposure of V79 cells to DEA/NO
resulted in approximately 33% increase in melphalan uptake. The
increase in melphalan uptake caused by the DEAINO treatment
could not account in a one-to-one fashion for all the melphalan
enhancement as the DEA/NO modification factor was greater than
30% (Figure 1). Although DEA/NO incubation does increase
intracellular melphalan levels, the increase may only explain a
portion ofthe enhanced cytotoxicity; however, we cannot exclude
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the possibility that the 30% increase in uptake is responsible for
the sensitization of melphalan by NO. However, reversing the
order of treatment (see Figure 5) also resulted in enhanced
melphalan cytotoxicity. This would rule out altered melphalan
uptake as a mechanism ofenhanced cytotoxicity.
Although not conclusive, the data presented in this study
suggest that NO treatment may inhibit melphalan damage repair.
One of the primary repair mechanisms for alkylating agents is
DNA repair. It has been shown that exposure ofcells to millimolar
concentrations of DEAINO inhibits specific DNA repair proteins
in intact cells (Laval and Wink, 1994; Wink and Laval, 1994). The
inhibition of these proteins has been shown to be mediated by
RNOS (Laval and Wink, 1994; Wink and Laval, 1994). Although
not all repair proteins are affected by NO or RNOS, those which
possess rich thiol regions such as zinc finger motifs can be inhib-
ited (Kroncke et al, 1994; Wink and Laval, 1994; Misra et al, 1995;
Schwarz et al, 1995). In fact, DEA/NO treatment results in loss of
activity to such proteins, even in whole cells (Wink and Laval,
1994). Thus, a possible mechanism for NO enhanced melphalan
cytotoxicity is that RNOS formed by DEA/NO exposure results in
damage to repair systems that subsequently inhibit the repair of
melphalan induced DNA damage. Whatever the actual mecha-
nism(s) of NO-induced sensitization of cells to treatment with
melphalan, our results show a potential avenue to improve
melphalan efficacy.
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